-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $83

Benzinga·08/20/2026 19:46:33
語音播報
Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $81 to $83.